Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWei LiuYWYi Wang

Discussion

Loading...

Member takes

Overview

Single-center study shows promising outcomes with CAR T-cell therapy and autologous stem cell transplantation, suggesting improvements in survival for relapsed/refractory large B-cell lymphoma.

Key Points

  • This research aims to evaluate the efficacy and safety of combining CAR T-cell therapy with autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphoma.
  • Retrospective analysis of patients receiving combination therapy at a single center.
  • Patients treated with either axicabtagene ciloleucel or relmacabtagene autoleucel combined with HDT/ASCT.
  • Outcomes measured included response rates, progression-free survival, and safety profiles.
  • Eighty-six percent of patients achieved an overall response rate after treatment.
  • The estimated 2-year progression-free survival rate was 65.2%.
  • Cytokine release syndrome occurred in 66.7% of patients, mostly mild (grades 1-2).

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df56https://doi.org/10.1182/blood-2025-3720
View Full Paper
Ask AI
Bookmark
Share